Biogen Presents Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab at 2016 Clinical Trials on Alzheimer’s Disease Meeting

Data Includes Analyses of Phase 1b Titration Cohort and Long-Term Extension Cohort. Biogen (NASDAQ: BIIB) announced it will present new data from the Phase 1b (PRIME) study of aducanumab, its investigational treatment for early Alzheimer’s disease (AD), today at the 9 th Clinical Trials on Alzheimer’s Disease (CTAD) meeting in San Diego.